Real World Experience with Regdanvimab Treatment of Mild-toModerate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea / 감염과화학요법
Infection and Chemotherapy
; : 114-124, 2022.
Artículo
en Inglés
| WPRIM (Pacífico Occidental)
| ID: wpr-925820
Biblioteca responsable:
WPRO
ABSTRACT
Background@#Real-world clinical data concerning regdanvimab, a monoclonal antibody treatment for patients with mild-to-moderate coronavirus disease 2019 (COVID-19), are urgently needed. Here, we describe our experience with regdanvimab. @*Materials and Methods@#This retrospective cohort study enrolled high-risk adults with mild-to-moderate COVID-19 who were admitted to a dedicated COVID-19 hospital in Korea from March to September 2021. We used multiple logistic regression and propensity scorematching to compare the outcomes of patients who did or did not receive regdanvimab. The primary outcome was in-hospital progression to severe or critical status, or death. @*Results@#Of 586 patients eligible for regdanvimab, 256 patients who received regdanvimab and 251 untreated patients were included. The median age was 66 years and 47.5% were men. The most common underlying illnesses were hypertension (53.8%) and diabetes (36.9%). Patients were admitted to the hospital at a median of 2 days after symptom onset; regdanvimab was administered at a median of 3 days after symptom onset. Multivariate analysis indicated that regdanvimab significantly reduced the risk of disease progression during hospitalization [odds ratio (OR) 0.285; 95% confidence interval (CI) 0.144 - 0.564].In a 11 propensity score-matched cohort (172 patients in either group), regdanvimab also decreased the risk of progression (OR 0.162; 95% CI 0.068 - 0.386). @*Conclusion@#In high-risk patients with mild-to-moderate COVID-19, regdanvimab decreased the risk of progression to severe COVID-19.
Texto completo:
Disponible
Contexto en salud:
ODS3 - Meta 3.3 Poner fin a las enfermedades desatendidas y detener enfermedades transmisibles
Problema de salud:
COVID-19
Base de datos:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Estudio observacional
Idioma:
Inglés
Revista:
Infection and Chemotherapy
Año:
2022
Tipo del documento:
Artículo